Co-Diagnostics, Inc. (CODX)
| Market Cap | 97.39M |
| Revenue (ttm) | 53.22M |
| Net Income (ttm) | 15.17M |
| Shares Out | 30.92M |
| EPS (ttm) | 0.47 |
| PE Ratio | 6.70 |
| Forward PE | 16.00 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 235,164 |
| Open | 3.21 |
| Previous Close | 3.24 |
| Day's Range | 3.15 - 3.33 |
| 52-Week Range | 2.26 - 7.35 |
| Beta | -0.53 |
| Analysts | Buy |
| Price Target | 11.90 (+277.78%) |
| Earnings Date | Mar 22, 2023 |
About CODX
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for ... [Read more]
Financial Performance
In 2021, Co-Diagnostics's revenue was $97.89 million, an increase of 31.30% compared to the previous year's $74.55 million. Earnings were $36.66 million, a decrease of -13.70%.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for CODX stock is "Buy." The 12-month stock price forecast is $11.9, which is an increase of 277.78% from the latest price.
News
Co-Diagnostics, Inc. Commemorates Third Anniversary of the Completion of its First COVID-19 Test Design
Designed using the Company's proprietary platform, initial test design remains effective detection tool even after three years of variants and more than 33 million sold worldwide; Company also announc...
Co-Diagnostics, Inc. to Present at the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022
SALT LAKE CITY , Nov. 30, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development o...
Co-Diagnostics, Inc. to Host Booth at MEDICA 2022 Trade Fair in Düsseldorf, Germany
SALT LAKE CITY , Nov. 14, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development o...
CoDiagnostics, Inc. (CODX) Reports Q3 Loss, Lags Revenue Estimates
CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of 33.33% and 24.53%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock...
Co-Diagnostics, Inc. Reports Third Quarter 2022 Financial Results
Nearing commencement of clinical evaluations for the Co-Dx PCR Home platform COVID-19 test volumes continue to impact third quarter results SALT LAKE CITY , Nov. 10, 2022 /PRNewswire/ -- Co-Diagnostic...
Co-Diagnostics, Inc. to Host Booth at AMP This Week in Phoenix, AZ
SALT LAKE CITY , Nov. 3, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of...
Co-Diagnostics, Inc. Appoints Dr. Mark Poritz as New Chief Scientific Officer
SALT LAKE CITY , Nov. 1, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of m...
CO-DIAGNOSTICS, INC. ANNOUNCES THIRD QUARTER 2022 EARNINGS RELEASE DATE AND WEBCAST
SALT LAKE CITY , Oct. 27, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, ...
Co-Diagnostics, Inc. to Host Booth at Medlab Africa on Oct 26-28 in South Africa
SALT LAKE CITY , Oct. 26, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development o...
Co-Diagnostics, Inc. to Host Booths at Conferences in Washington, D.C. and Bangkok, Thailand
SALT LAKE CITY , Oct. 19, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development o...
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Co-Diagnostics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 17, 2022 - (NASDAQ: CODX)
NEW YORK , Oct. 19, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Co-Diagnostics, Inc.. Shareholders who purchased shares of CODX during the class period liste...
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Co-Diagnostics (CODX) Investors of Today's Lead Plaintiff Deadline in Securities Class Action
San Francisco, California--(Newsfile Corp. - October 17, 2022) - Hagens Berman urges Co-Diagnostics, Inc. (NASDAQ: CODX) investors who suffered significant losses to submit your losses now. Class Peri...
DEADLINE TODAY: The Schall Law Firm Encourages Investors in Co-Diagnostics, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - October 17, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Co-Diagnostics, I...
Co-Dx Class Action: Levi & Korsinsky Reminds Co-Diagnostics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 17, 2022 - CODX
New York, New York--(Newsfile Corp. - October 16, 2022) - Levi & Korsinsky, LLP notifies investors in Co-Diagnostics, Inc. ("Co-Dx" or the "Company") (NASDAQ: CODX) of a class action securities lawsui...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Co-Diagnostics, Inc. of Class Action Lawsuit and Upcoming Deadline - CODX
New York, New York--(Newsfile Corp. - October 16, 2022) - Pomerantz LLP announces that a class action lawsuit has been filed against Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Dx" or the "Company") and ...
CODX FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Co-Diagnostics, Inc. Investors to Secure Counsel Before Important October 17 Deadline in Securities Class Action - CODX
NEW YORK , Oct. 14, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Co-Diagnostics, Inc. (NASDAQ: CODX) between May 12, 2022 and Au...
CODX SHAREHOLDER ALERT: Jakubowitz Law Reminds Co-Dx Shareholders of a Lead Plaintiff Deadline of October 17, 2022
NEW YORK , Oct. 14, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Co-Diagnostics, Inc. (NASDAQ: CODX). To receiv...
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Co-Diagnostics, Inc. (CODX) and Encourages Long-Term CODX Investors to Contact the Firm
PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating Co-Diagnostics, Inc. (“Co-Diagnostics” or the Company) (NASDAQ: CODX) on behalf of the Company's long-term investors.
CODX Deadline Notice: ROSEN, Leading Investor Counsel, Encourages Co-Diagnostics, Inc. Investors to Secure Counsel Before Important October 17 Deadline in Securities Class Action - CODX
New York, New York--(Newsfile Corp. - October 11, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Co-Diagnostics, Inc. (NASDAQ: CODX) between Ma...
CODX Final Notice: ROSEN, Top Ranked Investor Counsel, Encourages Co-Diagnostics, Inc. Investors to Secure Counsel Before Important October 17 Deadline in Securities Class Action - CODX
New York, New York--(Newsfile Corp. - October 9, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Co-Diagnostics, Inc. (NASDAQ: CODX) between May...
CODX LAWSUIT ALERT: Levi & Korsinsky Notifies Co-Diagnostics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK , Oct. 6, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Co-Diagnostics, Inc. ("Co-Dx" or the "Company") (NASDAQ: CODX) of a class action securities lawsuit. CLASS DEFINITIO...
CODX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 17, 2022 in the Class Action Filed on Behalf of Co-Diagnostics, Inc. Shareholders
NEW YORK , Oct. 4, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Co-Diagnostics, Inc. (NASDAQ: CODX) alleging that the Com...
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Co-Dx Investors of a Lead Plaintiff Deadline of October 17, 2022
NEW YORK , Oct. 3, 2022 /PRNewswire/ -- Attention Co-Diagnostics, Inc. ("Co-Dx") (NASDAQ: CODX) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on beha...
ROSEN, LEADING INVESTOR COUNSEL, Encourages Co-Diagnostics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CODX
New York, New York--(Newsfile Corp. - October 1, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Co-Diagnostics, Inc. (NASDAQ: CODX) between May...
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Co-Diagnostics (CODX) Investors with Significant Losses to Contact the Firm's Attorneys, Securities Class Action Pending
San Francisco, California--(Newsfile Corp. - September 30, 2022) - Hagens Berman urges Co-Diagnostics, Inc. (NASDAQ: CODX) investors who suffered significant losses to submit your losses now.Class Per...